Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1993 Aug;48(8):817–823. doi: 10.1136/thx.48.8.817

Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year. International Study Group.

L Fabbri 1, P S Burge 1, L Croonenborgh 1, F Warlies 1, B Weeke 1, A Ciaccia 1, C Parker 1
PMCID: PMC464708  PMID: 8211872

Abstract

BACKGROUND--High dose inhaled glucocorticosteroids are increasingly used in the management of patients with moderate to severe asthma. Although effective, they may cause systemic side effects. Fluticasone propionate is a topically active inhaled glucocorticosteroid which has few systemic effects at high doses. METHODS--Fluticasone propionate, 1.5 mg per day, was compared with beclomethasone dipropionate at the same dose for one year in patients with symptomatic moderate to severe asthma; 142 patients received fluticasone propionate and 132 received beclomethasone dipropionate. The study was multicentre, double blind and of a parallel design. For the first three months patients attended the clinic every four weeks and completed daily diary cards. For the next nine months they were only seen at three monthly intervals in the clinic. RESULTS--During the first three months diary card peak expiratory flow (PEF) rate and lung function measurements in the clinic showed significantly greater improvement in patients receiving fluticasone propionate (difference in morning PEF 15 l/min (95% CI 6 to 25)), and these differences were apparent at the end of the first week. The improved lung function was maintained throughout the 12 month period and the number of severe exacerbations in patients receiving fluticasone propionate was reduced by 8% compared with those receiving beclomethasone dipropionate. No significant differences between the two groups were observed in morning plasma cortisol levels, urinary free cortisol levels, or response to synthetic ACTH stimulation. In addition, both the rates of withdrawal and of adverse events were low, and there were fewer exacerbations of asthma with fluticasone propionate than beclomethasone dipropionate. CONCLUSIONS--This study shows that fluticasone propionate in a daily dose of 1.5 mg results in a significantly greater increase in PEF and asthma control than the same dose of beclomethasone dipropionate, with no increase in systemic or other side effects.

Full text

PDF
817

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ali N. J., Capewell S., Ward M. J. Bone turnover during high dose inhaled corticosteroid treatment. Thorax. 1991 Mar;46(3):160–164. doi: 10.1136/thx.46.3.160. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Boe J., Skoogh B. E. Is long-term treatment with inhaled steroids in adults hazardous? Eur Respir J. 1992 Oct;5(9):1037–1039. [PubMed] [Google Scholar]
  3. Brown P. H., Blundell G., Greening A. P., Crompton G. K. Hypothalamo-pituitary-adrenal axis suppression in asthmatics inhaling high dose corticosteroids. Respir Med. 1991 Nov;85(6):501–510. doi: 10.1016/s0954-6111(06)80268-4. [DOI] [PubMed] [Google Scholar]
  4. Ebden P., Jenkins A., Houston G., Davies B. H. Comparison of two high dose corticosteroid aerosol treatments, beclomethasone dipropionate (1500 micrograms/day) and budesonide (1600 micrograms/day), for chronic asthma. Thorax. 1986 Nov;41(11):869–874. doi: 10.1136/thx.41.11.869. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Geddes D. M. Inhaled corticosteroids: benefits and risks. Thorax. 1992 Jun;47(6):404–407. doi: 10.1136/thx.47.6.404. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Harding S. M. The human pharmacology of fluticasone propionate. Respir Med. 1990 Nov;84 (Suppl A):25–29. doi: 10.1016/s0954-6111(08)80004-2. [DOI] [PubMed] [Google Scholar]
  7. Laursen L. C., Taudorf E., Weeke B. High-dose inhaled budesonide in treatment of severe steroid-dependent asthma. Eur J Respir Dis. 1986 Jan;68(1):19–28. [PubMed] [Google Scholar]
  8. Phillipps G. H. Structure-activity relationships of topically active steroids: the selection of fluticasone propionate. Respir Med. 1990 Nov;84 (Suppl A):19–23. doi: 10.1016/s0954-6111(08)80003-0. [DOI] [PubMed] [Google Scholar]
  9. Rafferty P., Tucker L. G., Frame M. H., Fergusson R. J., Biggs B. A., Crompton G. K. Comparison of budesonide and beclomethasone dipropionate in patients with severe chronic asthma: assessment of relative prednisolone-sparing effects. Br J Dis Chest. 1985 Jul;79(3):244–250. [PubMed] [Google Scholar]
  10. Smith M. J., Hodson M. E. High-dose beclomethasone inhaler in the treatment of asthma. Lancet. 1983 Feb 5;1(8319):265–269. doi: 10.1016/s0140-6736(83)91686-0. [DOI] [PubMed] [Google Scholar]
  11. Willey R. F., Godden D. J., Carmichael J., Preston P., Frame M., Crompton G. K. Comparison of twice daily administration of a new corticosteroid budesonide with beclomethasone dipropionate four times daily in the treatment of chronic asthma. Br J Dis Chest. 1982 Jan;76(1):61–68. [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES